Literature DB >> 33075805

Conditional deletion of SMN in cell culture identifies functional SMN alleles.

Anton J Blatnik1,2, Vicki L McGovern2, Thanh T Le2, Chitra C Iyer2, Brian K Kaspar3, Arthur H M Burghes1,2,4,5.   

Abstract

Spinal muscular atrophy (SMA) is caused by mutation or deletion of survival motor neuron 1 (SMN1) and retention of SMN2 leading to SMN protein deficiency. We developed an immortalized mouse embryonic fibroblast (iMEF) line in which full-length wild-type Smn (flwt-Smn) can be conditionally deleted using Cre recombinase. iMEFs lacking flwt-Smn are not viable. We tested the SMA patient SMN1 missense mutation alleles A2G, D44V, A111G, E134K and T274I in these cells to determine which human SMN (huSMN) mutant alleles can function in the absence of flwt-Smn. All missense mutant alleles failed to rescue survival in the conditionally deleted iMEFs. Thus, the function lost by these mutations is essential to cell survival. However, co-expression of two different huSMN missense mutants can rescue iMEF survival and small nuclear ribonucleoprotein (snRNP) assembly, demonstrating intragenic complementation of SMN alleles. In addition, we show that a Smn protein lacking exon 2B can rescue iMEF survival and snRNP assembly in the absence of flwt-Smn, indicating exon 2B is not required for the essential function of Smn. For the first time, using this novel cell line, we can assay the function of SMN alleles in the complete absence of flwt-Smn.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2020        PMID: 33075805      PMCID: PMC7946624          DOI: 10.1093/hmg/ddaa229

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  82 in total

1.  Low levels of Survival Motor Neuron protein are sufficient for normal muscle function in the SMNΔ7 mouse model of SMA.

Authors:  Chitra C Iyer; Vicki L McGovern; Jason D Murray; Sara E Gombash; Phillip G Zaworski; Kevin D Foust; Paul M L Janssen; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2015-08-13       Impact factor: 6.150

2.  Correlation between severity and SMN protein level in spinal muscular atrophy.

Authors:  S Lefebvre; P Burlet; Q Liu; S Bertrandy; O Clermont; A Munnich; G Dreyfuss; J Melki
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

3.  Structural basis for dimethylarginine recognition by the Tudor domains of human SMN and SPF30 proteins.

Authors:  Konstantinos Tripsianes; Tobias Madl; Martin Machyna; Dimitrios Fessas; Clemens Englbrecht; Utz Fischer; Karla M Neugebauer; Michael Sattler
Journal:  Nat Struct Mol Biol       Date:  2011-11-20       Impact factor: 15.369

4.  A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy.

Authors:  C L Lorson; E Hahnen; E J Androphy; B Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype.

Authors:  Corey Ruhno; Vicki L McGovern; Matthew R Avenarius; Pamela J Snyder; Thomas W Prior; Flavia C Nery; Abdurrahman Muhtaseb; Jennifer S Roggenbuck; John T Kissel; Valeria A Sansone; Jennifer J Siranosian; Alec J Johnstone; Pann H Nwe; Ren Z Zhang; Kathryn J Swoboda; Arthur H M Burghes
Journal:  Hum Genet       Date:  2019-02-20       Impact factor: 4.132

6.  A cell system with targeted disruption of the SMN gene: functional conservation of the SMN protein and dependence of Gemin2 on SMN.

Authors:  J Wang; G Dreyfuss
Journal:  J Biol Chem       Date:  2000-12-19       Impact factor: 5.157

7.  A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy.

Authors:  Tsuyoshi Kashima; James L Manley
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

8.  The domain encoded by exon 2 of the survival motor neuron protein mediates nucleic acid binding.

Authors:  C L Lorson; E J Androphy
Journal:  Hum Mol Genet       Date:  1998-08       Impact factor: 6.150

9.  Structure of a key intermediate of the SMN complex reveals Gemin2's crucial function in snRNP assembly.

Authors:  Rundong Zhang; Byung Ran So; Pilong Li; Jeongsik Yong; Tina Glisovic; Lili Wan; Gideon Dreyfuss
Journal:  Cell       Date:  2011-08-05       Impact factor: 41.582

10.  Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons.

Authors:  Wilfried Rossoll; Sibylle Jablonka; Catia Andreassi; Ann-Kathrin Kröning; Kathrin Karle; Umrao R Monani; Michael Sendtner
Journal:  J Cell Biol       Date:  2003-11-17       Impact factor: 10.539

View more
  4 in total

1.  Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.

Authors:  Gretchen Thomsen; Arthur H M Burghes; Caroline Hsieh; Janet Do; Binh T T Chu; Stephanie Perry; Basam Barkho; Petra Kaufmann; Douglas M Sproule; Douglas E Feltner; Wendy K Chung; Vicki L McGovern; Robert F Hevner; Miriam Conces; Christopher R Pierson; Mariacristina Scoto; Francesco Muntoni; Jerry R Mendell; Kevin D Foust
Journal:  Nat Med       Date:  2021-10-04       Impact factor: 53.440

2.  Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice.

Authors:  Kaitlyn M Kray; Vicki L McGovern; Deepti Chugh; W David Arnold; Arthur H M Burghes
Journal:  Neurobiol Dis       Date:  2021-08-20       Impact factor: 5.996

3.  Identification and structural analysis of the Schizosaccharomyces pombe SMN complex.

Authors:  Jyotishman Veepaschit; Aravindan Viswanathan; Rémy Bordonné; Clemens Grimm; Utz Fischer
Journal:  Nucleic Acids Res       Date:  2021-07-21       Impact factor: 16.971

Review 4.  In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy.

Authors:  Kristine S Ojala; Emily J Reedich; Christine J DiDonato; Stephen D Meriney
Journal:  Brain Sci       Date:  2021-02-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.